Form 4: Zoetis CEO Kristin Peck Executes Stock Options and Sells Shares Under 10b5-1 Plan

Zoetis CEO Kristin Peck exercised stock options and sold a portion of the acquired shares, as disclosed in a Form 4 filing with the SEC.

Summary

• Kristin C. Peck, CEO of Zoetis Inc., executed stock options and sold shares of common stock on February 19, 2025.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2024.
• Peck exercised options to acquire 382 shares at a price of $46.09.
• She then sold 382 shares at a weighted average price of $156.6813, with individual sales ranging from $156.68 to $156.69.
• Following these transactions, Peck directly owns 94,194 shares of Zoetis common stock.
• She also indirectly owns 811.5333 shares through the Zoetis Inc. Savings Plan (401(k)).
• Peck holds options to purchase a total of 197,148 additional shares at various exercise prices and grant dates.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports stock option exercises and sales under a pre-arranged plan, which is a routine activity. There's no indication of positive or negative implications for the company's performance.

Positives

• The CEO's transactions are being conducted under a pre-arranged 10b5-1 trading plan, which can reassure investors that the sales are not based on insider information.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's performance and future prospects. The use of 10b5-1 plans is a standard practice to avoid insider trading concerns.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical and animal health industries often include stock options as a significant component.
• The vesting schedules and exercise prices of these options are typically structured to align executive incentives with long-term shareholder value creation.
• Companies like Elanco and Merck, which operate in similar sectors, also have executives who regularly exercise stock options and sell shares under pre-arranged trading plans.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely negligible given the relatively small number of shares involved.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates